Clinical Trial

Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls

Study acronym: OxySPECTRUM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication. This study seeks to test whether the oxytocin response after MDMA administration is different between individuals with autism spectrum disorder and matched healthy controls.
Trial Details
NCT Number NCT07555132
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Autism Spectrum Disorder
Enrollment 40 participants
Start Date 2026-06
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-29